Objectives: The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a psychometrically validated patient-reported outcome measure increasingly used in trials of treatments for multiple sclerosis. However, it is non-preference-based and not amenable for use across policy decision-making contexts. Our objective was to statistically map from the MSIS-29, version 2, to the EuroQol five-dimension (EQ-5D) and the six-dimension health state short form (derived from short form 36 health survey) (SF-6D) to estimate algorithms for use in costeffectiveness analyses. Methods: The relationships between MSIS-29, version 2, and EQ-5D and SF-6D scores were estimated by using data from a cohort of people with multiple sclerosis in South West England (n ¼ 672). Six ordinary least squares (OLS), Tobit, and censored least adjusted deviation (CLAD) regression analyses were conducted on estimation samples, including the use of subscale and item scores, squared and interaction terms, and demographics. Algorithms from models with the smallest estimation errors (mean absolute error [MAE], root mean square error [RMSE], normalized RMSE) were then assessed by using separate validation samples. Results: Tobit and CLAD. For the EQ-5D, the OLS models including subscale squared terms, and item scores and demographics performed comparably (MAE 0.147, RMSE 0.202 and MAE 0.147, RMSE 0.203, respectively), and estimated scores well up to 3 years post-baseline. Estimation errors for the SF-6D were smaller (OLS model including squared terms: MAE 0.058, RMSE 0.073; OLS model using item scores and demographics: MAE 0.059, RMSE 0.08), and the errors for poorer health states found with the EQ-5D were less pronounced. Conclusions: We have provided algorithms for the estimation of health state utility values, both the EQ-5D and SF-6D, from scores on the MSIS-29, version 2. Further research is now needed to determine how these algorithms perform in practical decision-making contexts, when compared with observed EQ-5D and SF-6D values.
Introduction
The use of clinical tools, such as the Expanded Disability Status Scale (EDSS) [1] , for the assessment of the impact of multiple sclerosis (MS) can describe symptoms, functional disability, and disease progression, but such measures are not able to capture the full impact of MS on people's lives, particularly in terms of their health-related quality of life (HRQOL) [2] . Over recent years, internationally [3] , across disease groups [4] , and specifically in the field of MS [2, 5] , there has been a move toward the use of patient-reported outcome measures, which aim to encapsulate these broader effects.
The 29-item Multiple Sclerosis Impact Scale (MSIS-29) [6, 7] was specifically constructed to assess the impact of MS on people's HRQOL in terms of their physical and psychological well-being. The measure is founded on qualitative interviews with people with MS and has been developed by using both traditional [8] and contemporary [7, 9] psychometric techniques. Its flexibility for use in different settings (e.g., hospital and community) has been demonstrated [10] , it can be completed by proxies [11] , it has been shown to be responsive over time [2, 12, 13] , and a minimally important difference has been suggested for its physical subscale [12] . The MSIS-29 is now in its second version [7] and given its strong foundations as a suitable outcome measure for clinical trials of the effectiveness of treatments for MS, it is being increasingly used.
However, health policy decision makers also increasingly need information on the comparative effectiveness and costeffectiveness of treatments across different disease groups. In its current form, the MSIS-29 is not amenable for use in this way, because it is not a preference-based measure [14] . Preferencebased measures use preference data, often elicited from general populations, to assign relative values to health state descriptions. Preference-based measures have two components: 1) a means of describing health status and 2) a mechanism for assigning health state utility values to each of the possible health states [15] . The health state utility values can be derived by a variety of methods and give values on a scale where 1 is equivalent to full health and 0 is equivalent to death. Data from preference-based measures are more amenable for use in health policy decision making, because preferences for the health states or outcomes associated with interventions can be compared across different conditions. Preference-based responses are also used to estimate qualityadjusted life-years (QALYs).
QALYs combine quantity and quality of life in a single measure of health outcome, by adjusting life-years survived using a quality-of-life weight, with the weight usually being health state utility values derived from preference data [15] . For example, a year in full health would equate to 1 QALY, and 2 years in ''half health'' (0.5 health state value) would also equate to 1 QALY. QALYs are the outcome of choice in a growing number of health policy settings [16] [17] [18] .
When an outcome measure, such as the MSIS-29, is not preference based, one solution to enable it to be used in comparative effectiveness and cost-effectiveness analyses is to statistically ''map'' it to a commonly used preference-based measure [19] such as the EuroQol five-dimension (EQ-5D) [20, 21] or the six-dimension health state short form (derived from the short form 36 health survey and the short form 12 health survey [SF-12]) (SF-6D) [22, 23] . In mapping studies, statistical regression analyses are used to map from a ''starting'' measure (e.g., the MSIS-29) to a ''target'' measure (e.g., the EQ-5D). The relationship between the measures is estimated, and algorithms of this relationship are derived. These algorithms can then be used with other data to convert non-preference-based measure scores (e.g., the MSIS-29) to preference-based measure scores (e.g., the EQ-5D).
''Mapping'' has become a fairly common approach and has been conducted in a wide range of disease areas, for example, in osteoarthritis [24] , cancer [25] , Crohn's disease [26] , and oral health [27] . Yet, the approach has been less used with neurological conditions.
Over the last decade, a number of new medicines have been licensed for the treatment of MS, but the evaluation of these medicines has been hampered by an absence of good quality data on the costs and, particularly, the benefits of these treatments [28] . This article estimates and tests mapping algorithms to convert MSIS-29, version 2 (v2), scores to EQ-5D and SF-6D health state utility values for use in assessing the comparative effectiveness and cost-effectiveness of treatments for people with MS.
Methods

The Data
Data from the UK South West Impact of Multiple Sclerosis (SWIMS) cohort were used for analysis. SWIMS is a longitudinal, prospective, cohort study of people with MS in Devon and Cornwall (South West England), with individuals followed-up every 6 months [29] . Data are collected on demographics and clinical features and across a range of patient-reported outcomes, including the MSIS-29 v2, the EQ-5D, and the SF-36. SWIMS commenced recruitment in August 2004, and all participants who had completed baseline questionnaires including complete MSIS-29 v2, the EQ-5D, the SF-36, and demographic (age and gender) data by February 2010 were included in this analysis.
The SWIMS study was approved in the United Kingdom by the Cornwall and Plymouth and South Devon Research Ethics Committees, and written informed consent was obtained from all participants.
Measures
MSIS-29 v2 [6, 7] The MSIS-29 is a 29 item, condition-specific, self-report questionnaire for measuring the impact of MS on people's lives. It has two subscales: a 20-item physical impact scale and a 9-item psychological impact scale (and no total score). It is currently in its second version, which has four-point response categories for each item: ''not at all,'' ''a little,'' ''moderately,'' and ''extremely.'' Scores on the physical impact scale can range from 20 to 80 and on the psychological impact scale from 9 to 36, with lower scores indicating little impact of MS and higher scores indicating greater impact.
The EQ-5D [20] The EQ-5D is a generic health status measure comprising five subscales (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with each subscale having three response levels (1, ''no problems''; 2, ''moderate problems''; 3, ''severe problems''). This classification of health status results in 243 possible health state descriptions.
Participant responses to the EQ-5D can be converted to the EQ-5D derived single index, a generic preference-based measure, using preference weights for the health states. For example, in the United Kingdom, values that have been derived from the preferences of a general population sample for each of the 243 possible health states are commonly used [21] . This gives values for each of the EQ-5D health states on an index ranging from 1.00 for the best health state to À 0.594 for the worst health state. The EQ-5D is frequently used in clinical studies and costeffectiveness analyses, and it is currently the measure preferred by the UK National Institute of Health and Clinical Excellence in its health technology appraisals process [16] .
SF-36/SF-6D [22, 23] The SF-36, currently in its second version, includes 36 self-report questions regarding functional health and well-being. Participant responses can be converted to a single index by using preference weights elicited against SF-36-derived health states. For example, scores are commonly converted to SF-6D health state utility values by using valuations elicited from a representative sample of the UK general population [23] . Scores on the SF-6D can range from 0.3 to 1.0, where 0.3 indicates the worst health state and 1.0 the best health state.
Data Analyses
The rigor of the mapping approach rests on there being a considerable overlap between the descriptive systems of the ''starting'' measure and the ''target'' measure [19] . The overlap between the MSIS-29 and the EQ-5D and between the MSIS-29 and the SF-6D would be expected to be substantial as each of the measures assesses HRQOL. A diagrammatic representation of the areas of joint coverage is given in Fig. 1 .
Statistical conventions in the mapping literature [19] were followed to examine the relationships between the MSIS-29 and the EQ-5D index and between the MSIS-29 and the SF-6D. For the EQ-5D, baseline data from SWIMS were used as the estimation sample to develop the most appropriate statistical models and to test within-sample predictive performance. The predictive accuracy of the best performing subscale scores and item scores models was then assessed by using longitudinal data from SWIMS (the validation sample). In the SWIMS data, only at baseline are MSIS-29 and SF-36 data collected at the same time.
In follow-up questionnaires, SF-36 and MSIS-29 questionnaires are used in alternating six-monthly data collection. Therefore, the analysis here of the SF-6D data uses only baseline data, with a random sample of 75% of the SWIMS baseline data used for estimating SF-6D algorithms (the estimation sample) and 25% of the SWIMS baseline data used for assessing their predictive accuracy (the validation sample) [30] .
Six regression models were estimated for both of the EQ-5D and the SF-6D.
The EQ-5D index/SF-6D scores were regressed onto the following: Multicollinearity of the MSIS-29 items was assessed by using the ''collin'' command in STATA. As a result, items 2, 4, 7, 9, 10, 17, 20, 21, 22, 23, 24, 26, 27, and 28 were included in the items analyses (models E and F). The items that were not statistically significant were then removed from the models.
Ordinary least squares (OLS) regression models were used for estimation as OLS has been used in the majority of mapping studies, with the suggestion that more complex models may not add predictive power or reduce errors in prediction [31] . Concerns, however, have been raised about the use of OLS, for example, in underestimating variance in individual predicted scores [32] and, in a practical context, in underestimating QALY gains [33] . Therefore, Tobit models [34] and the censored least adjusted deviation (CLAD) method of estimation [35] were also used to test their value in further reducing estimation errors. Tobit models have been used for modeling health state value data as an upper censoring limit of 1 can be defined [36, 37] . This is likely to be particularly applicable to EQ-5D data, which are known to exhibit ceiling effects [38, 39] , but may aid the estimation of SF-6D scores, which also have an upper limit of (or are censored at) 1. However, Tobit models are sensitive to violations of hetereoscedasticity or nonnormality [36] , and CLAD has become popular in the mapping literature as it is thought to be robust to such violations [40] [41] [42] .
When mapping, the principal aim is not to produce a model that explains the most variance in the data (adjusted R 2 ) but to derive an algorithm that as accurately as possible estimates health state utility values at a group level [43] . Therefore, for each of the regression models (36 in total), estimation errors [19] , in the form of mean absolute error (MAE) and root mean square error (RMSE), were assessed. MAE is the mean of the absolute estimation errors across individuals (the estimation error is the difference between the actual EQ-5D/SF-6D score for a particular individual and their estimated EQ-5D/SF-6D score based on the mapping model). RMSE is the positive square root of the mean squared estimation error. There are currently no guidelines as to when estimation errors are and are not accep- Versteegh et al. [44] highlight that MAE and RMSE are not comparable for models that map to different preference-based measures, as a larger scale size usually leads to larger error figures. For example, estimation errors might be expected to be greater on the EQ-5D than on the SF-6D as the former is on a scale from À 0.594 to 1 and the latter on a scale from 0.3 to 1. As such, normalized RMSEs [45] were calculated here, which give RMSE as a percentage of the preference-based measure scale size.
Also assessed were the proportions of estimates that fell within 0.05, 0.10, and 0.25 of the actual EQ-5D/SF-6D value.
The predictive accuracy of the algorithms with the lowest prediction errors was then assessed. The actual EQ-5D scores were compared with the estimated scores at a number of followup points in the SWIMS data, and the actual SF-6D scores were compared with the estimated scores in the validation sample at baseline. Prediction errors were also assessed according to differing severities of EQ-5D/SF-6D health states.
Data analysis was conducted in STATA 10.
Results
EQ-5D
Predictive performance (estimation sample)
A total of 672 of the 827 (81.3%) SWIMS participants gave complete EQ-5D and MSIS-29 v2 data at baseline. Their demographic and clinical characteristics are shown in Table 1 . EQ-5D scores ranged from À 0.429 to 1 and were bimodally distributed with a mean 7 SD of 0.612 7 0.288. The correlations between the physical impact scale and EQ-5D scores and the psychological impact scale and EQ-5D scores were À 0.708 and À 0.492, respectively (both significant at P o 0.001).
The 18 models performed broadly similarly in predicting EQ-5D health state utility values from the MSIS-29 data. The OLS models performed the best, followed by the Tobit models, and the CLAD method of estimation performed least well (see Appendix Fig. 1 -Overlap between the descriptive systems of the MSIS-29 and the EQ-5D/SF-6D. EQ-5D, EuroQol fivedimension; MSIS-29, the 29-item Multiple Sclerosis Impact Scale; SF-6D, six-dimension health state short form (derived from short form 36 health survey). model using just the subscale scores (model B) (MAE 0.147; % RMSE 12.7) was also assessed for predictive accuracy. In addition, the best performing algorithm based on item scores (OLS model F: MAE 0.147; % RMSE 12.7) and the items model without the inclusion of age and gender (OLS model E: MAE 0.149; % RMSE 12. 9) were also tested for predictive accuracy.
Predictive accuracy (longitudinal data)
The validation sample comprised SWIMS follow-up data across 10 time points, based on participants who provided complete MSIS-29 and EQ-5D data (responses ¼ 2461). The estimated EQ-5D scores, as compared with the actual scores for each of the OLS models, at each of the time points are given in Table 2 . These data show the similarity of the estimated and actual mean EQ-5D scores. The models performed well at estimating scores up to 3 years post-baseline, after which there was generally a slight increase in error.
The errors in the longitudinal sample for each of the models tested for predictive accuracy are given in Appendix 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2012.07. 007 and in Fig. 2 by differing degrees of health state severity. The errors for the OLS models using subscale scores (model B: MAE 0. 162, % RMSE 13.6; model D: MAE 0.164, % RMSE 13.6) were less than the errors for the models that used item scores (model E: MAE 0.167, % RMSE 13.8; model F: MAE 0.167, % RMSE 13.7).
For the four models assessed for predictive accuracy, prediction errors reduced incrementally as the EQ-5D scores increased; that is, predictions consistently improved as health state utility values improved (Fig. 2) .
The details of the best performing subscale scores and item scores algorithms are given in Tables 3 and 4 .
SF-6D
A total of 660 of the 819 (80.6%) SWIMS participants fully completed both the MSIS-29 v2 and the SF-36 v2 at baseline. Four hundred and ninety-five individuals were randomly assigned to the estimation sample and 165 to the validation sample.
Predictive performance (estimation sample)
The demographic and clinical characteristics of the estimation sample are given in Table 1 . SF-6D scores ranged from 0.301 to 1, with a mean 7 SD of 0.637 7 0.133. The correlation between SF-6D and physical impact scale scores was À 0.760, and the correlation between SF-6D and psychological impact scale scores was À 0.668 (both significant at P o 0.001).
The 18 models performed comparably in predicting SF-6D scores (see Appendix 2 in Supplemental Materials found at http:// dx.doi.org/10.1016/j.jval.2012.07.007). The Tobit models and the CLAD method of estimation offered no advantage in terms of estimation errors over the OLS models. The OLS model based on MSIS-29 subscale scores and subscale scores squared (model B) was the most accurate in its estimations (MAE 0.058; % RMSE 10. 3). The OLS model (F) based on MSIS-29 item scores and participant demographics (MAE 0.064; % RMSE 11.4) and the OLS items model without the inclusion of age and gender (model E: MAE 0.064; % RMSE 11.6) were also tested for predictive accuracy.
Predictive accuracy (validation sample)
The validation sample comprised the remaining 25% of the SWIMS participants who provided complete MSIS-29 v2 and SF-36 data at baseline (n ¼ 165). Their mean 7 SD physical impact scale and psychological impact scale scores were 41.55 7 15.27 and 17.63 7 6.12, respectively, and their mean 7 SD SF-6D score was 0.639 7 0.128. The estimated SF-6D scores, as compared with the actual scores for each of the models, are given in Table 2 . Prediction errors in the validation sample for all the models tested are given in Appendix 2 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2012.07.007. These were very similar to those found in the estimation sample, particularly for the OLS subscales and subscales squared model (model B: MAE 0. 059; % RMSE 10.4%). There was no added value in terms of prediction errors in using an items model (model E: MAE 0.068, % RMSE 12.1; model F: MAE 0.067, % RMSE 12.0). For the three models assessed for predictive accuracy, the prediction errors were slightly higher when estimating the poorer SF-6D health states as compared with the better SF-6D health states (Fig. 3) , but this was not as apparent as when EQ-5D scores were estimated. Details of the best performing subscale scores and item scores algorithms are given in Tables 3 and 4 .
Conclusions
This article gives a method by which health state utility values can be estimated (or mapped) from scores on the MSIS-29, enabling assessment of the cost-effectiveness, and the broader impact, of treatments for people with MS. The algorithms presented can be applied to MSIS-29 v2 subscale scores and/or item scores, for estimating both EQ-5D and SF-6D health state utility values. These algorithms compare well, in statistical terms, to other published mapping studies [19] . They are applicable to broad populations of people with MS as the SWIMS sample that they were derived from was heterogeneous, as shown by the wide range of ages, MS subtypes, and EQ-5D, SF-6D, and MSIS-29 scores, and there was a high proportion of complete MSIS-29 and EQ-5D (81.3%) and SF-6D (80.6%) responses given by the cohort.
This research sits against a backdrop of very little mapping relating to neurological conditions. One study has mapped from the Parkinson's Disease Questionnaire [41] and, more recently, Versteegh et al. [44] have provided algorithms to estimate EQ-5D scores from version 1 of the MSIS-29. The current study provides a useful complement to this work for the revised version of the questionnaire; analogous methods have been used in the generation of algorithms, and the resulting estimation errors are very similar (for MAE, RMSE, and normalized RMSE). In addition, algorithms are presented in the current study for the SF-6D as well as for the EQ-5D.
Results show that models predict well for both the SF-6D and the EQ-5D. The models, however, worked better at estimating SF-6D, rather than EQ-5D, health state utility values as the prediction errors (normalized RMSE) for the SF-6D were consistently lower. The greater success of the SF-6D models is likely to be explained by two factors: 1) the more normal distribution of SF-6D scores (and its compressed scale) as compared with the bimodal distribution of EQ-5D scores, making the SF-6D more amenable for use in regression analyses, and 2) the greater overlap in content between the SF-6D and the MSIS-29, as compared with the overlap between the EQ-5D and the MSIS-29. This is shown in Figure 1 and also by the higher correlations, particularly for the psychological impact scale. (The SF-6D is derived from the SF-36, which has a specific mental component subscale.) The algorithms overpredicted EQ-5D values when estimating for the more severe health states (Fig. 2) , a common finding in mapping studies [43] , but this was not marked when estimating SF-6D values. In an attempt to ameliorate the overpredictions found with the EQ-5D, we used a variety of two-part regression models, as suggested in the literature, for example, [30, 44] . These did not improve the errors found. However, in the context of economic evaluations, comparisons are primarily made across groups and individual predictions are less important than the effect of prediction errors at the group level [43] . Only 6% of the sample here had scores below 0.04 (the minimum score predicted by the best performing EQ-5D model), meaning that these errors may have little impact on the comparison of health state utility values at a group level, in a policy context, particularly in specific evaluation settings where the target group is in the mild-tomoderate spectrum of disease severity. The appropriateness of using mapping, and the validity of the resulting algorithms, rests on there being significant overlap in the content of the measures being mapped [19] . Information is, inevitably, lost in the conversion process, and less similarity between the scales increases the theoretical uncertainty of what is retained by the resulting conversion function [46] . This being said, there is a high degree of overlap and correlation between the MSIS-29 v2 and the EQ-5D and between the MSIS-29 and the SF-6D. In addition, the issue of theoretical uncertainty may well be an academic consideration in the practical context of using mapped data. If health state utility values can be accurately estimated from scores on the non-preference-based measure (as is the case with the MSIS-29 and the EQ-5D/SF-6D), the nature of what is lost in the mapping algorithm may receive limited attention. The findings presented here have demonstrated that it is possible to estimate health state utility values for two of the most commonly used preference-based measures, the EQ-5D and the SF-6D, from individual participant scores on the MSIS-29 v2. Further research is needed to consider how the mapping algorithms derived here perform in practical policy contexts when compared with observed EQ-5D and SF-6D values. The algorithms can provide broadly applicable information about the HRQOL of people affected by MS and inform the framework for assessing the cost-effectiveness of new and existing treatments for MS.
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